Out of these, 111 women (45.7%) had Luminal A breast cancer, 67 (27.6%) had Luminal B, 17 (7.0%) had HER2-positive breast cancer, and 36 women (14.9%) were triple-negative. Here, ERBB2 is linked to breast cancer.